Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

LigaChem Biosciences stock

141080.KQ
KR7141080002

Price

106,500.00
Today +/-
+0.60
Today %
+0.85 %

LigaChem Biosciences stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the LigaChem Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the LigaChem Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the LigaChem Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze LigaChem Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

LigaChem Biosciences Stock Price History

DateLigaChem Biosciences Price
12/4/2024106,500.00 undefined
12/3/2024105,600.00 undefined
12/2/202497,900.00 undefined
11/29/202495,500.00 undefined
11/28/202499,400.00 undefined
11/27/202496,100.00 undefined
11/26/202494,300.00 undefined
11/25/202499,200.00 undefined
11/22/202495,500.00 undefined
11/21/202497,000.00 undefined
11/20/2024101,600.00 undefined
11/19/2024106,300.00 undefined
11/18/2024113,200.00 undefined
11/15/2024120,000.00 undefined
11/14/2024118,900.00 undefined
11/13/2024120,700.00 undefined
11/12/2024132,600.00 undefined
11/11/2024140,000.00 undefined
11/8/2024130,600.00 undefined
11/7/2024125,200.00 undefined
11/6/2024131,700.00 undefined

LigaChem Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into LigaChem Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by LigaChem Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects LigaChem Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of LigaChem Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into LigaChem Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing LigaChem Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on LigaChem Biosciences’s growth potential.

LigaChem Biosciences Revenue, EBIT and net profit per share

DateLigaChem Biosciences RevenueLigaChem Biosciences EBITLigaChem Biosciences Net Income
2026e233.98 B undefined53.34 B undefined47.52 B undefined
2025e244.86 B undefined88.43 B undefined55.37 B undefined
2024e132.49 B undefined17.61 B undefined8.52 B undefined
202334.15 B undefined-80.82 B undefined-73.7 B undefined
202233.41 B undefined-50.38 B undefined-45.09 B undefined
202132.16 B undefined-27.71 B undefined-23.39 B undefined
202049.39 B undefined-29.76 B undefined-6.99 B undefined
201957.5 B undefined8.42 B undefined13.59 B undefined
201825.24 B undefined-15.98 B undefined-25.77 B undefined
201722.06 B undefined-9.84 B undefined-12.93 B undefined
201616.66 B undefined-10.17 B undefined-14.73 B undefined
20151.79 B undefined-8.05 B undefined-8.24 B undefined
2014870 M undefined-8.46 B undefined-8.69 B undefined
2013840 M undefined-6.26 B undefined-5.84 B undefined
2012744 M undefined-3.25 B undefined-2.67 B undefined
201179 M undefined-3.06 B undefined-3.07 B undefined
2010270 M undefined-3.07 B undefined-3.34 B undefined
20091.7 B undefined-429 M undefined-466 M undefined
2008338 M undefined-1.27 B undefined-1.27 B undefined

LigaChem Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0.341.70.270.080.740.840.871.7916.6622.0625.2457.549.3932.1633.4134.15132.49244.86233.98
-402.37-84.10-70.74841.7712.903.57105.52831.4932.4314.43127.81-14.10-34.903.902.19288.0384.81-4.44
39.9441.523.3367.0968.012,118.692,045.6361.4125.1730.4723.4160.5472.0055.0353.4252.1213.437.277.61
0.140.710.010.050.51001.14.196.725.9134.8135.5717.717.8517.8000
-1.27-0.47-3.34-3.07-2.67-5.84-8.69-8.24-14.73-12.93-25.7713.59-6.99-23.39-45.09-73.78.5255.3747.52
--63.34616.09-8.00-12.90118.2148.86-5.1778.77-12.1699.24-152.72-151.42234.8392.7763.45-111.56549.82-14.17
789911131415192021242324.1224.3628.4000
-------------------
Details

Keystats

Revenue and Growth

The LigaChem Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the LigaChem Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (B)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
200820092010201120122013201420152016201720182019202020212022
                             
3.657.964.415.945.4820.0530.0319.13021.2361.742.2151.24170.9462.39
0.080.040.050.050.060.780.269.2612.715.6217.811.3420.6922.5913.33
0.070.030.110.040.070.020.150.320.470.348.5545.8511.4523.93103.06
0.03-00000000.440.940.762.020.290.270.2
0.060.120.160.270.880.230.180.946.017.094.5810.0116.3511.2112.64
3.898.154.736.296.521.0930.6229.6249.6245.2193.38111.42100.01228.95191.62
0.260.230.190.190.21.21.163.496.877.8510.2812.147.6224.4326.49
00000010.993.93.925.197.3316.5222.6319.82
900220000010010010000095.84
0.280.450.010.010.040.060.1213.7312.4411.3610.118.998.158.67.89
000000019.1314.3311.4700000
0.020.010.040.120.180.810.861.472.292.352.641.63.628.626.61
0.650.690.250.320.432.073.1438.8239.9337.0328.3130.0635.964.2860.91
4.538.844.996.616.9223.1633.7668.4489.5582.24121.69141.48135.91293.23252.53
                             
1.161.441.291.792.763.573.834.524.974.986612.0513.6213.83
3.156.834.7113.0114.0434.0844.6575.33106.53107.52185.49186.65183.14349.7993.88
-3.05-3.48-7.47-10.67-13.45-19.56-28.43-36.67-51.44-64.29-90.29-78.81-86.14-109.59105.38
00000000000.47-0.102.54.71
0000000000003.082.451.79
1.254.78-1.474.133.3518.0820.0443.1860.0648.21101.67113.75112.13258.77219.6
00000006.067.579.128.187.696.566.857.28
0.010.010.040.050.050.070.10.130.180.170.140.360.220.423.88
0.380.590.460.651.761.830.831.21.081.661.637.267.156.95.41
00000001.80000002.7
02.570.020.020.020006.176.700.110.082.869.33
0.383.170.520.721.831.890.939.191517.649.9515.4214.0117.0228.6
2.470.094.060.050.031.059.079.837.858.5202.073.919.410.22
0000001.033.943.923.362.412.881.253.931.13
0.430.81.881.711.722.132.692.312.713.264.035.194.624.12.98
2.90.885.941.761.743.1812.7916.0814.4915.136.4510.149.7817.444.33
3.294.056.462.483.575.0713.7125.2629.4932.7716.3925.5723.7934.4632.93
4.538.844.996.616.9223.1533.7668.4489.5580.98118.06139.32135.91293.23252.53
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of LigaChem Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand LigaChem Biosciences's financial health and stability.

Assets

LigaChem Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that LigaChem Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of LigaChem Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into LigaChem Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200820092010201120122013201420152016201720182019202020212022
-1.27-0.47-3.34-3.07-2.67-5.84-8.69-8.24-14.7312.93-26.0712.48-6.99-23.39-45.09
0.090.370.10.10.080.220.340.392.152.642.783.872.993.054.12
00000000000000-2
-0.030.260.170.480.85-0.38-0.26-1.43-5.79-27.94-1.089.14-8.38-24.7720.48
0.280.290.530.02-0.56-0.110.710.735.334.1611.62-1.37-2.523.0613.37
001743501363071199403751287
00-4-107-641112381467504-3882385
-0.940.44-2.54-2.48-2.31-6.1-7.88-8.54-13.04-8.21-12.7624.11-14.89-42.05-7.14
-318-544-161-209-141-1,234-290-365-4,242-2,541-3,970-3,491-3,219-18,603-4,772
1.2-4.512.64-0.880.81-16.07-10.929.17-20.1511.89-50.5929.970.35-43.94-16.17
1.52-3.972.81-0.670.95-14.83-10.639.54-15.9114.44-46.6233.463.57-25.34-11.4
000000000000000
00-0.89-0.02-0.020.9611.408.7002.341.328.03-0.19
0404.07221.777.680.225.031.9860.470.271.47163.293.39
0.194.29-0.894.051.9721.7419.080.1933.721.9864.942.62.63171.293.2
0.190.3-00-0.01-0.990-0.01-0.0104.47-0-0.16-0.03-0
000000000000000
0.450.22-0.780.680.47-0.420.280.820.535.651.656.67-12.2485.29-21.98
-1,255-100-2,701-2,693-2,451-7,334-8,172-8,908-17,281-10,754-16,72820,622-18,112-60,651.78-11,907.71
000000000000000

LigaChem Biosciences stock margins

The LigaChem Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of LigaChem Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for LigaChem Biosciences.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the LigaChem Biosciences's sales revenue. A higher gross margin percentage indicates that the LigaChem Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the LigaChem Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the LigaChem Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the LigaChem Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the LigaChem Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the LigaChem Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

LigaChem Biosciences Margin History

LigaChem Biosciences Gross marginLigaChem Biosciences Profit marginLigaChem Biosciences EBIT marginLigaChem Biosciences Profit margin
2026e52.12 %22.8 %20.31 %
2025e52.12 %36.12 %22.61 %
2024e52.12 %13.29 %6.43 %
202352.12 %-236.7 %-215.85 %
202253.42 %-150.77 %-134.96 %
202155.03 %-86.16 %-72.74 %
202072 %-60.25 %-14.14 %
201960.54 %14.64 %23.63 %
201823.41 %-63.3 %-102.1 %
201730.47 %-44.62 %-58.64 %
201625.17 %-61.08 %-88.41 %
201561.41 %-450.17 %-460.68 %
201452.12 %-972.07 %-998.39 %
201352.12 %-745.24 %-694.64 %
201268.01 %-437.1 %-359.41 %
201167.09 %-3,875.95 %-3,886.08 %
20103.33 %-1,135.56 %-1,235.93 %
200941.52 %-25.27 %-27.44 %
200839.94 %-376.33 %-376.04 %

LigaChem Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The LigaChem Biosciences earnings per share therefore indicates how much revenue LigaChem Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue LigaChem Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates LigaChem Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of LigaChem Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating LigaChem Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LigaChem Biosciences Revenue, EBIT and net profit per share

DateLigaChem Biosciences Sales per ShareLigaChem Biosciences EBIT per shareLigaChem Biosciences Earnings per Share
2026e6,415.49 undefined0 undefined1,302.95 undefined
2025e6,713.87 undefined0 undefined1,518.1 undefined
2024e3,632.93 undefined0 undefined233.62 undefined
20231,202.14 undefined-2,845.45 undefined-2,594.83 undefined
20221,371.43 undefined-2,067.7 undefined-1,850.84 undefined
20211,332.94 undefined-1,148.47 undefined-969.59 undefined
20202,147.57 undefined-1,294 undefined-303.74 undefined
20192,395.83 undefined350.71 undefined566.08 undefined
20181,201.9 undefined-760.86 undefined-1,227.14 undefined
20171,102.85 undefined-492.1 undefined-646.7 undefined
2016876.58 undefined-535.42 undefined-775 undefined
2015119.2 undefined-536.6 undefined-549.13 undefined
201462.14 undefined-604.07 undefined-620.43 undefined
201364.62 undefined-481.54 undefined-448.85 undefined
201267.64 undefined-295.64 undefined-243.09 undefined
20118.78 undefined-340.22 undefined-341.11 undefined
201030 undefined-340.67 undefined-370.78 undefined
2009212.25 undefined-53.63 undefined-58.25 undefined
200848.29 undefined-181.71 undefined-181.57 undefined

LigaChem Biosciences business model

LigaChem Biosciences is one of the most popular companies on Eulerpool.com.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

LigaChem Biosciences Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

LigaChem Biosciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

LigaChem Biosciences shares outstanding

The number of shares was LigaChem Biosciences in 2023 — This indicates how many shares 28.404 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue LigaChem Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates LigaChem Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of LigaChem Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating LigaChem Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LigaChem Biosciences stock splits

In LigaChem Biosciences's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for LigaChem Biosciences.

LigaChem Biosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024107.65 328  (204.68 %)2024 Q3
6/30/2024131.44 -269  (-304.66 %)2024 Q2
1

LigaChem Biosciences shareholders

%
Name
Stocks
Change
Date
25.67372 % Pan Orion Corp Limited.9,363,28306/30/2024
3.36281 % Kim (Yong Ju)1,226,42806/30/2024
1.98262 % The Vanguard Group, Inc.723,067233,5019/30/2024
1.22532 % Samsung Asset Management Co., Ltd.446,8792959/30/2024
0.79814 % BlackRock Institutional Trust Company, N.A.291,0831,0569/30/2024
0.64434 % Mirae Asset Global Investments Co., Ltd.234,9911,1498/31/2024
0.56786 % JPMorgan Asset Management (Asia Pacific) Limited207,10052,5009/30/2024
0.49774 % Park (Se Jin)181,52806/30/2024
0.46455 % Franklin Templeton International Services SARL169,423-22,3516/30/2024
0.36533 % Norges Bank Investment Management (NBIM)133,238-59,4796/30/2024
1
2
3
4
5
...
8

Most common questions regarding LigaChem Biosciences

What is the P/E ratio of LigaChem Biosciences 2024?

The LigaChem Biosciences P/E ratio is 355.04.

What is the P/S ratio of LigaChem Biosciences 2024?

The LigaChem Biosciences P/S ratio is 22.83.

What is the Quality Investing of LigaChem Biosciences?

The Quality Investing for LigaChem Biosciences is 5/10.

What is the revenue of LigaChem Biosciences 2024?

The expected LigaChem Biosciences revenue is 132.49 B KRW.

How high is the profit of LigaChem Biosciences 2024?

The expected LigaChem Biosciences profit is 8.52 B KRW.

What is the business model of LigaChem Biosciences

No history available for LigaChem Biosciences.

What is the LigaChem Biosciences dividend?

LigaChem Biosciences pays a dividend of 0 KRW distributed over payouts per year.

How often does LigaChem Biosciences pay dividends?

The dividend cannot currently be calculated for LigaChem Biosciences or the company does not pay out a dividend.

What is the LigaChem Biosciences ISIN?

The ISIN of LigaChem Biosciences is KR7141080002.

What is the LigaChem Biosciences ticker?

The ticker of LigaChem Biosciences is 141080.KQ.

How much dividend does LigaChem Biosciences pay?

Over the past 12 months, LigaChem Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, LigaChem Biosciences is expected to pay a dividend of 0 KRW.

What is the dividend yield of LigaChem Biosciences?

The current dividend yield of LigaChem Biosciences is .

When does LigaChem Biosciences pay dividends?

LigaChem Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of LigaChem Biosciences?

LigaChem Biosciences paid dividends every year for the past 0 years.

What is the dividend of LigaChem Biosciences?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is LigaChem Biosciences located?

LigaChem Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von LigaChem Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of LigaChem Biosciences from 12/5/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.

When did LigaChem Biosciences pay the last dividend?

The last dividend was paid out on 12/5/2024.

What was the dividend of LigaChem Biosciences in the year 2023?

In the year 2023, LigaChem Biosciences distributed 0 KRW as dividends.

In which currency does LigaChem Biosciences pay out the dividend?

The dividends of LigaChem Biosciences are distributed in KRW.

All fundamentals about LigaChem Biosciences

Our stock analysis for LigaChem Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of LigaChem Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.